These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 23974099)

  • 1. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
    Leontieva OV; Blagosklonny MV
    Cell Cycle; 2013 Sep; 12(18):3063-9. PubMed ID: 23974099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK drives cyclin D1 hyperelevation during geroconversion.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Death Differ; 2013 Sep; 20(9):1241-9. PubMed ID: 23852369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
    Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
    Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin, proliferation and geroconversion to senescence.
    Blagosklonny MV
    Cell Cycle; 2018; 17(24):2655-2665. PubMed ID: 30541374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts.
    Stein GH; Drullinger LF; Soulard A; Dulić V
    Mol Cell Biol; 1999 Mar; 19(3):2109-17. PubMed ID: 10022898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
    Paternot S; Colleoni B; Bisteau X; Roger PP
    Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
    Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
    Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.
    Wang R; Yu Z; Sunchu B; Shoaf J; Dang I; Zhao S; Caples K; Bradley L; Beaver LM; Ho E; Löhr CV; Perez VI
    Aging Cell; 2017 Jun; 16(3):564-574. PubMed ID: 28371119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin decelerates cellular senescence.
    Demidenko ZN; Zubova SG; Bukreeva EI; Pospelov VA; Pospelova TV; Blagosklonny MV
    Cell Cycle; 2009 Jun; 8(12):1888-95. PubMed ID: 19471117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia suppresses conversion from proliferative arrest to cellular senescence.
    Leontieva OV; Natarajan V; Demidenko ZN; Burdelya LG; Gudkov AV; Blagosklonny MV
    Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13314-8. PubMed ID: 22847439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells.
    Leontieva OV; Lenzo F; Demidenko ZN; Blagosklonny MV
    Cell Cycle; 2012 Dec; 11(24):4642-9. PubMed ID: 23187803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S6K in geroconversion.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Cycle; 2013 Oct; 12(20):3249-52. PubMed ID: 24036549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8832-7. PubMed ID: 24889617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
    Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
    Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis.
    Capparelli C; Chiavarina B; Whitaker-Menezes D; Pestell TG; Pestell RG; Hulit J; Andò S; Howell A; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
    Cell Cycle; 2012 Oct; 11(19):3599-610. PubMed ID: 22935696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
    Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
    Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms.
    Ruas M; Gregory F; Jones R; Poolman R; Starborg M; Rowe J; Brookes S; Peters G
    Mol Cell Biol; 2007 Jun; 27(12):4273-82. PubMed ID: 17420273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Oncotarget; 2015 Sep; 6(27):23238-48. PubMed ID: 26177051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
    Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
    Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
    Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
    Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.